CanSino Biologics (KG:6185, SHA:688185) said Malaysia's National Pharmaceutical Regulatory Agency has granted a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for its vaccine manufacturing site, according to a Thursday Hong Kong bourse filing.
Hong Kong-listed shares of the firm were up nearly 1% in Friday morning trade.
The certification covers production of the Group ACYW135 meningococcal polysaccharide conjugate vaccine (MCV4) and the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments